A Phase III Trial of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vinflunine (Primary) ; Capecitabine
Indications Advanced breast cancer
Focus Registrational; Therapeutic Use
Sponsors Pierre Fabre

Most Recent Events

12 Oct 2014 According to UKCRN record, planned number of patients reported as 764.
11 Jun 2014 Planned End Date changed from 1 Apr 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
03 Jun 2014 Primary endpoint 'Progression-free-survival' has been met.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight